Cargando…

Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome

Some patients with pollen-food allergy syndrome (PFAS) develop systemic symptoms along with oral allergy syndrome upon ingesting processed foods as well as raw fruits and vegetables. This study aimed to investigate the efficacy of subcutaneous immunotherapy with birch pollen extract for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Masaaki, Kagawa, Masakazu, Tanaka, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563098/
https://www.ncbi.nlm.nih.gov/pubmed/34786369
http://dx.doi.org/10.5415/apallergy.2021.11.e39
_version_ 1784593362627592192
author Hamada, Masaaki
Kagawa, Masakazu
Tanaka, Ichiro
author_facet Hamada, Masaaki
Kagawa, Masakazu
Tanaka, Ichiro
author_sort Hamada, Masaaki
collection PubMed
description Some patients with pollen-food allergy syndrome (PFAS) develop systemic symptoms along with oral allergy syndrome upon ingesting processed foods as well as raw fruits and vegetables. This study aimed to investigate the efficacy of subcutaneous immunotherapy with birch pollen extract for patients with PFAS associated with soybean allergy. Subcutaneous immunotherapy with birch pollen extract was introduced in 6 patients with PFAS caused by alder/birch pollen and soybean allergy. An oral food challenge for ingestible amount of soy milk was performed before and 1 year after initiating subcutaneous immunotherapy with birch pollen extract. Before the treatment, the median intake of soy milk was 1.5 mL (interquartile range [IQR], 1–2 mL). One year after the treatment initiation, the median intake of soy milk increased significantly to 150 mL (IQR, 20–200 mL). Systemic reactions occurred in 4 of 6 patients in the rapid escalation phase of the treatment. The results thus suggest that subcutaneous immunotherapy with birch pollen extract could be beneficial for patients with PFAS associated with soybean allergy despite concerns regarding systemic reactions.
format Online
Article
Text
id pubmed-8563098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Asia Pacific Association of Allergy, Asthma and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-85630982021-11-15 Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome Hamada, Masaaki Kagawa, Masakazu Tanaka, Ichiro Asia Pac Allergy Hypothesis & Experience Some patients with pollen-food allergy syndrome (PFAS) develop systemic symptoms along with oral allergy syndrome upon ingesting processed foods as well as raw fruits and vegetables. This study aimed to investigate the efficacy of subcutaneous immunotherapy with birch pollen extract for patients with PFAS associated with soybean allergy. Subcutaneous immunotherapy with birch pollen extract was introduced in 6 patients with PFAS caused by alder/birch pollen and soybean allergy. An oral food challenge for ingestible amount of soy milk was performed before and 1 year after initiating subcutaneous immunotherapy with birch pollen extract. Before the treatment, the median intake of soy milk was 1.5 mL (interquartile range [IQR], 1–2 mL). One year after the treatment initiation, the median intake of soy milk increased significantly to 150 mL (IQR, 20–200 mL). Systemic reactions occurred in 4 of 6 patients in the rapid escalation phase of the treatment. The results thus suggest that subcutaneous immunotherapy with birch pollen extract could be beneficial for patients with PFAS associated with soybean allergy despite concerns regarding systemic reactions. Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2021-10-19 /pmc/articles/PMC8563098/ /pubmed/34786369 http://dx.doi.org/10.5415/apallergy.2021.11.e39 Text en Copyright © 2021. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hypothesis & Experience
Hamada, Masaaki
Kagawa, Masakazu
Tanaka, Ichiro
Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title_full Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title_fullStr Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title_full_unstemmed Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title_short Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
title_sort evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
topic Hypothesis & Experience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563098/
https://www.ncbi.nlm.nih.gov/pubmed/34786369
http://dx.doi.org/10.5415/apallergy.2021.11.e39
work_keys_str_mv AT hamadamasaaki evaluationofsubcutaneousimmunotherapywithbirchpollenextractforpollenfoodallergysyndrome
AT kagawamasakazu evaluationofsubcutaneousimmunotherapywithbirchpollenextractforpollenfoodallergysyndrome
AT tanakaichiro evaluationofsubcutaneousimmunotherapywithbirchpollenextractforpollenfoodallergysyndrome